热门资讯> 正文

Inhibikase Therapeutics GAAP每股收益为-0.11美元

2025-08-15 18:38

Inhibikase Therapeutics press release (NASDAQ:IKT): Q2 GAAP EPS of -$0.11.
As of June 30, 2025, cash, cash equivalents and marketable securities were $87.7 million as compared to $97.5 million as of December 31, 2024.

More on Inhibikase Therapeutics

Seeking Alpha’s Quant Rating on Inhibikase Therapeutics
Historical earnings data for Inhibikase Therapeutics
Financial information for Inhibikase Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。